Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone versus glipizide for progression of coronary atherosclerosis in type 2 diabetes mellitus with cardiovascular disease
2004-004090-29Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and atherosclerosis comparing Rosiglitazone arm with Glipizide arm (2 arms). Primary endpoint: Change in percent atheroma volume. Started Dec 2004; status: completed.
02
Drugs
rosiglitazoneglipizide
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on 2004-004090-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004090-29.